GCNT2 and acute myeloid leukemia: These results suggested the oncogenic driver of GCNT2 in AML, and the down-regulation of GCNT2 in AML could be explained by the fact that the silence of GCNT2 was a protective effect, whereas the reactivation of GCNT2 indeed contributed to a worse outcome.